Adjuvant therapy for hormone receptor-positive breast cancer: Perspective from a survey on breast cancer physicians' acceptance of practice-changing data  

作　　者：Asian Institute of Clinical Oncology(AICO)Expert Panel Louis W.C.Chow 

机构地区：[1]不详 [2]Organisation for Oncology and Translational Research,Unit 1604,16/F,Strand 50,50 Bonham Strand,Sheung Wan,Hong Kong SAR,China

出　　处：《Chinese Journal of Cancer Research》2023年第2期191-196,共6页中国癌症研究（英文版）

摘　　要：A cross-sectional online survey was conducted.A high proportion of the Chinese breast cancer(BC)physician respondents(n=77)would prescribe extended adjuvant endocrine therapy(AET)with aromatase inhibitors(AI)beyond 5 years for postmenopausal females with BC,especially those with higher risk.Respondents with≥15 years of clinical experience were more likely to prescribe a longer duration of AET for low-risk patients.Half of the respondents considered intermittent letrozole as an acceptable option.Most respondents would prescribe adjuvant chemotherapy to genomic high-intermediate risk[Oncotype DX recurrence score(RS)21-25]females aged≤50 years regardless of the clinical risk classification.

关 键 词：Breast neoplasms surveys and questionnaires CHEMOTHERAPY ADJUVANT practice patterns PHYSICIANS 

分 类 号：R737.9[医药卫生—肿瘤]